Monroe Capital Provides $20 Million Credit Facility to Cytovance Biologics, Inc.
Chicago, IL, October 28, 2014
Monroe Capital LLC today announced it acted as sole lead arranger and administrative agent on the funding of a $20 million senior credit facility to support the growth of Cytovance Biologics, Inc. (“Cytovance”) by private equity sponsor, Great Point Partners.
Based in Oklahoma City, Oklahoma, Cytovance is a contract manufacturing organization (“CMO”) of mammalian and microbial biologics. The company works with biotechnology and pharmaceutical companies in the development and manufacturing of proteins, antibodies, and cell-based therapeutic products. Cytovance supports its customers from clinical development to commercial launch in domestic and international markets.
This transaction is representative of Monroe Capital’s extensive capabilities in its healthcare vertical.
About Monroe Capital
Monroe Capital LLC is a leading provider of senior and junior debt and equity co-investments to middle-market companies in the U.S. and Canada. Investment types include unitranche financings, cash flow and enterprise value based loans, acquisition facilities, mezzanine debt, second lien or last-out loans and equity co-investments. Monroe Capital prides itself on its flexible investment approach and its ability to close and fund transactions quickly. Monroe is committed to being a value-added and user-friendly partner to owners, senior management and private equity sponsors. Monroe has been recognized by Global M&A Network as the 2013 Small Mid Market Lender of the Year and by Private Debt Investor as the 2013 Unitranche Lender of the Year. To learn more about Monroe Capital LLC, visit www.monroecap.com.